Home > News > Foreword – European Ophthalmic Review, 2016;10(1):13
Anterior Segment
Read Time: 2 mins

Foreword – European Ophthalmic Review, 2016;10(1):13

Published Online: August 9th 2016 European Ophthalmic Review, 2016;10(1):13
Authors: Maurizio Battaglia Parodi
Quick Links:
Article
Article Information
Article:

Welcome to the latest edition of European Ophthalmic Review, which features a wide range of articles, beginning with intraocular diseases. An editorial from Rodrigues and Lim explores approaches to achieving successful outcomes and minimising complications in neovascular glaucoma surgery. Also on the subject of glaucoma, Feijoo discusses the latest advances in tonometry. Biologic targeted therapies are transforming the treatment of uveitis. Taylor discusses the latest clinical advances in this field.

Optical coherence tomography angiography (OCTA) is an emerging, non-invasive imaging technique that generates three-dimensional images without the need for intravenous dyes. This technology has numerous potential applications for retinal vascular disease. Turgut and Reznicek each present reviews of the advantages and disadvantages of OCTA. In addition, Iuliano describes the application of OCTA to chorodial neovascularisations.

Diabetic macular oedema continues to present a major health challenge worldwide. Augustin presents a review of findings from clinical trials and real-world studies. While clinical trial data have shown comparable outcomes between vascular endothelial growth factor (VEGF) inhibitors and corticosteroids, real-world findings suggest that lower injection frequencies of VEGF are associated with less impressive outcomes. Sustained delivery of corticosteroids has shown similar efficacy in clinical and real-world studies.

Age-related macular degeneration (AMD) is the leading cause of vision loss in the elderly. In an expert review of a symposium presented at the 15th EURETINA Congress, Korobelnik et al discuss the use of aflibercept in AMD, including recent real-world data indicating that aflibercept can be given with reduced dosing frequency.

Finally, Michels and Wirth present an update of the management of branch retinal vein occlusion, including established and emerging treatment options.

European Ophthalmic Review would like to thank our Editorial Board for their continuing support and guidance. A special thanks also goes to our authors, who gave their time and effort to produce an insightful selection of articles. The expert discussions and the range of topics covered ensure there is something of interest for every reader and we hope you find this edition useful.

Article Information:

Further Resources

Share this Article
Related Content In Anterior Segment
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72